The 5th Annual Aging and Drug Discovery Forum at the Basel Life Conference 2018


Monday, August 20th, Rockville, MD – Insilico Medicine, a Rockville-based company specializing in the application of next-generation artificial intelligence for drug discovery, biomarker development and research in aging and longevity today announced that it will present the latest insights into the biomarkers of aging at the 5th Annual Aging Research for Drug Discovery Forum in Basel, Switzerland, September 12-13, 2018.

Many areas of science and technology are experiencing rapid advances and the exponential increase in knowledge base. Aging research is no exception. Multiple areas of science and technology are rapidly converging and governments all over the world are recognizing the economic benefits of increasing productive longevity and reducing the health care costs via the preventative and personalized approaches.

Alex Zhavoronkov, PhD, the CEO of Insilico Medicine will open the forum and moderate an expert panel discussions – the view from both academic, top investors and industry on where and how commercialization of aging and longevity research will likely occur. "Aging research is gaining credibility and some of the largest pharmaceutical, biotechnology and nutritional companies are launching research programs to translate these new insights into products. For the fifth year in a row Insilico Medicine is co-organizing the Aging Forum during the Basel Life Science Week and bringing together world's top thought leaders in the field. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems", said Dr. Alex Zhavoronkov.

Ivan Ozerov, PhD, the Drug Discovery Director of Insilico Medicine will present the talk "Multi-stage longevity therapeutics to fight aging at every level" on the 12th of September. "Several recent observations support the hypothesis that senescence can be a highly dynamic, multi-step process, during which the properties of senescent cells continuously evolve and diversify, much like tumorigenesis but without cell proliferation as a driver. Accordingly combinational therapies may be highly beneficial for the treatment of senescence associated conditions" – commented Dr. Ivan Ozerov.

Insilico Medicine was the first company to use deep learning to integrate multiple data types from multiple sources to accurately predict the chronological age of the patient, interpret the most important features and apply transfer learning techniques to age-related diseases.

The 5th Annual Aging and Drug Discovery Forum at the EMBO/Basel Life Conference transpiring in Basel, September 12-13 is co-organized by Morten Scheibye-Knudsen, MD, PhD, the head of the biology of aging laboratory at the University of Copenhagen. The forum will feature the talks of some of the industry's most prominent scientists and entrepreneurs. Morten Scheibye-Knudsen will present the talk "Exploring the phenotypical landscape of aging". "Aging is arguably the most complex of phenotypes, however the nature of the events leading to age-associated pathologies is largely unknown. Several presenters at the Aging and Drug Discovery forum will examine how diseases such as diabetes, neurodegeneration, and cancer emerge as part of the aging phenotype. Importantly, this knowledge also allows us to develop interventions targeting aging and age-associated diseases. Our goal: to allow everyone to live healthier and longer lives!" said Dr. Morten Scheibye-Knudsen.


To register for the forum, please visit:, the latest updates you can also find on our Facebook event.

About the Scheibye-Knudsen Laboratory

The growing proportion of the elderly population represents an increasing socioeconomic challenge, not least because of age-associated diseases. It is therefore increasingly pertinent to find interventions for age-associated diseases such as Alzheimer's, Parkinson's and cardiovascular diseases. Although the cause of aging is currently unknown accumulation of damage to our genome, the DNA, may be a contributing factor.

In the Scheibye-Knudsen lab we try to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.

Laboratory website:

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions. The company and its scientists is dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video:

Official Forum Website:

Media Contact

Qingsong Zhu
[email protected]

Leave A Reply

Your email address will not be published.